Sort
48,018 grants matching “immunotherapy”
Pre-clinical testing of a novel immunotherapy for HTLV-induced neurologic disease
$431,433Pooja Jain · Drexel University · R01 · FY2021 · NS
Pre-clinical testing of a novel immunotherapy for HTLV-induced neurologic disease
$431,433Pooja Jain · Drexel University · R01 · FY2018 · NS
Pre-clinical testing of a novel immunotherapy for HTLV-induced neurologic disease
$431,433Pooja Jain · Drexel University · R01 · FY2019 · NS
Improving genetically engineered T cells for medulloblastomas
$431,432Giedre Krenciute · St. Jude Children'S Research Hospital · R01 · FY2024 · NS
Influences of HLA Class I Polymorphisms on immune responses
$431,392Malini Raghavan · University Of Michigan At Ann Arbor · R01 · FY2016 · AI
Influences of HLA Class I Polymorphisms on immune responses
$431,392Malini Raghavan · University Of Michigan At Ann Arbor · R01 · FY2017 · AI
Influences of HLA Class I Polymorphisms on immune responses
$431,392Malini Raghavan · University Of Michigan At Ann Arbor · R01 · FY2015 · AI
Immune activation by necroptotic cell death
$431,384Andrew Atwell Oberst · University Of Washington · R01 · FY2020 · CA
Mechanisms Used by NKT Cells in the Control of Liver Tumors
$431,351Robert Wiltrout · Division Of Basic Sciences - Nci · ZIA · FY2012 · CA
Immune Checkpoints and HPV-associated Head and Neck Cancers
$431,300Sara Isabel Pai · Massachusetts General Hospital · R01 · FY2016 · DE
Immune Checkpoints and HPV-associated Head and Neck Cancers
$431,300Sara Isabel Pai · Massachusetts General Hospital · R01 · FY2015 · DE
Augmenting Anti-Tumor Immunity Using Radiation in the Setting of DNA Repair Defects
$431,284Simona Shaitelman · University Of Tx Md Anderson Can Ctr · R21 · FY2020 · CA
Resource for Nonhuman Primate Immune Reagents
$431,279Francois J Villinger · University Of Louisiana At Lafayette · R24 · FY2023 · OD
eRapa for bladder cancer prevention
$431,224Robert Scott Svatek · University Of Texas Hlth Science Center · R01 · FY2024 · CA
Radioimmunotherapy Combinations for B-cell Malignancy
$431,181Damian J. Green · Fred Hutchinson Cancer Research Center · R01 · FY2021 · CA
Ex vivo Analysis of Autoreactive T Cells from Patients with Multiple Sclerosis
$431,176John Christopher Love · Dana-Farber Cancer Inst · P01 · FY2016 · AI
Innate immune regulation of mAb-induced infusion reactions
$431,147Michael Rusty Elliott · University Of South Alabama · R21 · FY2025 · AI
Northern New Jersey Community Clinical Oncology Program
$431,140Hackensack University Medical Center · U10 · FY2002 · CA
Achieving Therapeutic Antigent-Specific Tolerance in Type 1 Diabetes
$431,123Matthias G. Von Herrath · La Jolla Institute For Immunology · U01 · FY2008 · DK
Mechanisms of immunotherapy response and resistance in pancreatic ductal adenocarcinoma
$431,094Ingunn Margarete Stromnes · University Of Minnesota · R01 · FY2021 · CA
Modulating pathogenic T cells in Type 1 diabetes
$431,038Kevan C Herold · Yale University · R01 · FY2020 · DK
Role of microbial-modulated bile acid receptor signaling in breast cancer
$431,028Liza Makowski Hayes · University Of Tennessee Health Sci Ctr · R01 · FY2022 · CA
Clinical protocols for the treatment of gastrointestinal cancer
$431,019Tim Greten · Division Of Basic Sciences - Nci · ZIA · FY2021 · CA
Role of GPR120 and Macrophages in Dietary Omega-3 Fatty Acid Inhibition of Prostate Cancer
$430,969William J Aronson · University Of California Los Angeles · R01 · FY2021 · CA
Role of GPR120 and Macrophages in Dietary Omega-3 Fatty Acid Inhibition of Prostate Cancer
$430,969William J Aronson · University Of California Los Angeles · R01 · FY2020 · CA